News

Daiichi Sankyo has reported the top line results from a phase III study of the anti-influenza virus agent, CS-8958. The study, named MARVEL (Multinational Asian Clinical Research for

Inovio has sealed a research collaboration agreement with the National Institutes of Health (NIH)’s Vaccine Research Center (VRC), to develop influenza vaccines. Under the agreement, VRC and Inovio

PTC Therapeutics (PTC) has received a research milestone of $2m in its collaboration with Schering-Plough. The payment is in connection with the designation of a development candidate for

Dendreon has signed a lease agreement with Majestic Realty Co. to build a 160,000 square-foot manufacturing facility in Union City, Georgia. The company expects to manufacture PROVENGE (sipuleucel-T),

Taro Pharmaceutical has provided preliminary results for the six months ended June 30, 2009. The company estimates net sales of $181.7m compared to $166.2m in the same period

APP Pharmaceuticals (APP), a wholly-owned subsidiary of Fresenius Kabi, has received approval from FDA to market idarubicin hydrochloride injection in three dosage strengths (5mg/5mL, 10mg/10mL and 20mg/20mL). APP

Seattle Genetics has received a milestone under its antibody-drug conjugate (ADC) collaboration agreement with MedImmune. The milestone was triggered by MedImmune’s initiation of a phase I clinical trial

Millipore has acquired Oxford, UK-based BioAnaLab. The transaction enables Millipore to expand its biopharmaceutical services business into Europe and strengthen its position in the biopharmaceutical industry. The services

Astellas Pharma (Astellas) reported that FDA has substantially denied its Citizen Petition to ensure the safe and effective use of immunosuppressants, used to prevent rejection in organ transplant